biostudies-literatureUnknown25(6)Caulley L<h4>Purpose</h4>The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary adenomas, direct surgery (that is, surgery without preoperative treatment) from a public third-party payer perspective.<h4>Methods</h4>We developed an individual-level state-transition microsimulation model to simulate costs and outcomes associated with preoperative octreotide therapy followed by surgery and direct surgery for patients with growth-hormone secreting pituitary adenomas. Transition probabilities, utilities, and costs were estimated from recent published data and discounted by 3% annually over a lifetime time horizon. Model outcomes included lifetime costs [2020 UniPituitary868-881https://www.ebi.ac.uk/biostudies/studies/S-EPMC9675692biostudies-literatureCost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.PMC9675692Alkherayf FDoyle MAQuinn JThavorn KSchramm DCaulley LKrijkamp EJohnson-Obaseki SDong SXHunink MGMSahlollbey NKilty SJfalseCost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.<h4>Purpose</h4>The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary adenomas, direct surgery (that is, surgery without preoperative treatment) from a public third-party payer perspective.<h4>Methods</h4>We developed an individual-level state-transition microsimulation model to simulate costs and outcomes associated with preoperative octreotide therapy followed by surgery and direct surgery for patients with growth-hormone secreting pituitary adenomas. Transition probabilities, utilities, and costs were estimated from recent published data and discounted by 3% annually over a lifetime time horizon. Model outcomes included lifetime costs [2020 Uni2022-01-01T00:00:00Z2022 Dec2025-04-25T21:05:17.528Z2025-04-06T08:35:20.628ZS-EPMC96756923603036010.1007/s11102-022-01270-8